CoChat

NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?

Open access
Sorce, Silvia, Stocker, Roland, Seredenina, Tamara, Holmdahl, Rikard, Aguzzi, Adriano, Chio, Adriano, Depaulis, Antoine, Heitz, Freddy, Olofsson, Peter, Olsson, Tomas, Duveau, Venceslas, Sanoudou, Despina, Skosgater, Sara, Vlahou, Antonia, Wasquel, Dominique, Krause, Karl-Heinz, Jaquet, Vincent · 2017 · Free Radical Biology and Medicine
Cited by 115

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Neurodegenerative disease are frequently characterized by microglia activation and/or leukocyte infiltration in the parenchyma of the central nervous system and at the molecular level by increased oxidative modifications of proteins, lipids and nucleic acids. NADPH oxidases (NOX) emerged as a novel promising class of pharmacological targets for the treatment of neurodegeneration due to their role in oxidant generation and presumably in regulating microglia activation. The unique function of NOX is the generation of superoxide anion (O2•–) and hydrogen peroxide (H2O2). However in the context of neuroinflammation, they present paradoxical features since O2•–/H2O2 generated by NOX and/or secondary reactive oxygen species (ROS) derived from O2•–/H2O2 can either lead to neuronal oxidative damage or resolution of inflammation. The role of NOX enzymes has been investigated in many models of neurodegenerative diseases by using either genetic or pharmacological approaches. In the present review we provide a critical assessment of recent findings related to the role of NOX in the CNS as well as how the field has advanced over the last 5 years. In particular, we focus on the data derived from the work of a consortium (Neurinox) funded by the European Commission's Programme 7 (FP7). We discuss the evidence gathered from animal models and human samples linking NOX expression/activity with neuroinflammation in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Creutzfeldt–Jakob disease as well as autoimmune demyelinating diseases like multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP). We address the possibility to use measurement of the activity of the NOX2 isoform in blood samples as biomarker of disease severity and treatment efficacy in neurodegenerative disease. Finally we clarify key controversial aspects in the field of NOX, such as NOX cellular expression in the brain, measurement of NOX activity, impact of genetic deletion of NOX in animal models of neurodegeneration and specificity of NOX inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.freeradbiomed.2017.08.006

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 115

Metadata

Authors
Sorce, S., Stocker, R., Seredenina, T., Holmdahl, R., Aguzzi, A., Chio, A., Depaulis, A., Heitz, F., Olofsson, P., Olsson, T., Duveau, V., Sanoudou, D., Skosgater, S., Vlahou, A., Wasquel, D., Krause, K.-H., & Jaquet, V.
Venue
Free Radical Biology and Medicine
Publisher
Elsevier BV
Published
2017-11
Volume
112
Pages
387-396
ISSN
0891-5849 (ISSN-L)
OpenAlex
W2746658569
Cited by
115
References
19
FWCI
3.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence? https://app.cochat.ai/papers/10.1016/j.freeradbiomed.2017.08.006
The paper
Sorce, S., Stocker, R., Seredenina, T., Holmdahl, R., Aguzzi, A., Chio, A., Depaulis, A., Heitz, F., Olofsson, P., Olsson, T., Duveau, V., Sanoudou, D., Skosgater, S., Vlahou, A., Wasquel, D., Krause, K.-H., & Jaquet, V. (2017). NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence? Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2017.08.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.